{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T00:49:05Z","timestamp":1790642945010,"version":"4.1.0"},"reference-count":56,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,6]],"date-time":"2018-10-06T00:00:00Z","timestamp":1538784000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Takeda Pharmaceuticals"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Hematology, Transfusion and Cell Therapy"],"published-print":{"date-parts":[[2019,1]]},"DOI":"10.1016\/j.htct.2018.07.003","type":"journal-article","created":{"date-parts":[[2018,10,15]],"date-time":"2018-10-15T14:17:55Z","timestamp":1539613075000},"page":"76-83","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["New proteasome inhibitors in the treatment of multiple myeloma"],"prefix":"10.1016","volume":"41","author":[{"given":"Vania Tietsche de Moraes","family":"Hungria","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edvan de Queiroz","family":"Cruso\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rosane Isabel","family":"Bittencourt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angelo","family":"Maiolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto Jos\u00e9 Pessoa","family":"Magalh\u00e3es","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jairo do Nascimento","family":"Sobrinho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorge Vaz","family":"Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ricardo Coutinho","family":"Fortes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eloisa de S\u00e1","family":"Moreira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paula Yurie","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0285","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mayocp.2015.11.007","article-title":"Multiple myeloma: diagnosis and treatment","volume":"91","author":"Rajkumar","year":"2016","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.1016\/j.htct.2018.07.003_bib0290","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1111\/ejh.12790","article-title":"Prevalence of symptoms in patients with multiple myeloma: a systematic review and meta-analysis","volume":"97","author":"Ramsenthaler","year":"2016","journal-title":"Eur J Haematol"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0295","first-page":"7","article-title":"Cancer statistics, 2017","volume":"67","author":"Siegel","year":"2017","journal-title":"CA: Cancer J Clin"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0300","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00277-016-2866-9","article-title":"Observational study of multiple myeloma in Latin America","volume":"96","author":"Hungria","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"10.1016\/j.htct.2018.07.003_bib0305","doi-asserted-by":"crossref","first-page":"791","DOI":"10.3324\/haematol.11637","article-title":"Confirmation of the utility of the International Staging System and identification of a unique pattern of disease in Brazilian patients with multiple myeloma","volume":"93","author":"Hungria","year":"2008","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2018.07.003_bib0310","doi-asserted-by":"crossref","first-page":"17046","DOI":"10.1038\/nrdp.2017.46","article-title":"Multiple myeloma","volume":"3","author":"Kumar","year":"2017","journal-title":"Nat Rev Dis Primers"},{"issue":"7","key":"10.1016\/j.htct.2018.07.003_bib0315","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/nrclinonc.2016.206","article-title":"Proteasome inhibitors in cancer therapy","volume":"14","author":"Manasanch","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"2","key":"10.1016\/j.htct.2018.07.003_bib0320","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/nrclinonc.2016.122","article-title":"Genomic complexity of multiple myeloma and its clinical implications","volume":"14","author":"Manier","year":"2017","journal-title":"Nat Rev Clin Oncol"},{"issue":"3","key":"10.1016\/j.htct.2018.07.003_bib0325","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.soncn.2017.05.005","article-title":"Immunomodulatory agents and proteasome inhibitors in the treatment of multiple myeloma","volume":"33","author":"Noonan","year":"2017","journal-title":"Semin Oncol Nurs"},{"issue":"7","key":"10.1016\/j.htct.2018.07.003_bib0330","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1177\/2040620717710171","article-title":"The potential of ixazomib, a second-generation proteasome inhibitor, in the treatment of multiple myeloma","volume":"8","author":"Brayer","year":"2017","journal-title":"Ther Adv Hematol"},{"issue":"36","key":"10.1016\/j.htct.2018.07.003_bib0335","doi-asserted-by":"crossref","first-page":"60656","DOI":"10.18632\/oncotarget.19269","article-title":"Emerging drugs and combinations to treat multiple myeloma","volume":"8","author":"Larocca","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.htct.2018.07.003_bib0340","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1158\/1535-7163.MCT-12-0782","article-title":"Endoplasmic reticulum stress and the unfolded protein response: targeting the Achilles heel of multiple myeloma","volume":"12","author":"Vincenz","year":"2013","journal-title":"Mol Cancer Ther"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0345","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.leukres.2013.10.018","article-title":"New orally active proteasome inhibitors in multiple myeloma","volume":"38","author":"Allegra","year":"2014","journal-title":"Leuk Res"},{"issue":"2","key":"10.1016\/j.htct.2018.07.003_bib0350","doi-asserted-by":"crossref","DOI":"10.3390\/ph10020040","article-title":"Novel proteasome inhibitors and histone deacetylase inhibitors: progress in myeloma therapeutics","volume":"10","author":"Chhabra","year":"2017","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.htct.2018.07.003_bib0355","doi-asserted-by":"crossref","first-page":"541984","DOI":"10.1155\/2015\/541984","article-title":"New insights into the function of the immunoproteasome in immune and nonimmune cells","volume":"2015","author":"Kimura","year":"2015","journal-title":"J Immunol Res"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0360","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1186\/s13045-016-0282-1","article-title":"Novel agents in the treatment of multiple myeloma: a review about the future","volume":"9","author":"Naymagon","year":"2016","journal-title":"J Hematol Oncol"},{"issue":"6","key":"10.1016\/j.htct.2018.07.003_bib0365","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1111\/ejh.12749","article-title":"A practical review on carfilzomib in multiple myeloma","volume":"96","author":"Muchtar","year":"2016","journal-title":"Eur J Haematol"},{"issue":"9","key":"10.1016\/j.htct.2018.07.003_bib0370","doi-asserted-by":"crossref","first-page":"906","DOI":"10.1056\/NEJMoa0801479","article-title":"Bortezomib plus melphalan and prednisone for initial treatment of multiple myeloma","volume":"359","author":"San Miguel","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2018.07.003_bib0375","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2147\/CMAR.S138932","article-title":"Induction regimens for transplant-eligible patients with newly diagnosed multiple myeloma: a network meta-analysis of randomized controlled trials","volume":"9","author":"Zeng","year":"2017","journal-title":"Cancer Manag Res"},{"issue":"9758","key":"10.1016\/j.htct.2018.07.003_bib0380","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.htct.2018.07.003_bib0385","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1200\/JCO.2012.48.4626","article-title":"Bortezomib-based versus nonbortezomib-based induction treatment before autologous stem-cell transplantation in patients with previously untreated multiple myeloma: a meta-analysis of phase III randomized, controlled trials","volume":"31","author":"Sonneveld","year":"2013","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.1016\/j.htct.2018.07.003_bib0390","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1097\/CAD.0000000000000506","article-title":"Bortezomib pharmacokinetics in tumor response and peripheral neuropathy in multiple myeloma patients receiving bortezomib-containing therapy","volume":"28","author":"Lee","year":"2017","journal-title":"Anticancer Drugs"},{"issue":"6","key":"10.1016\/j.htct.2018.07.003_bib0395","doi-asserted-by":"crossref","first-page":"517","DOI":"10.2174\/1568009614666140804154511","article-title":"Overview of proteasome inhibitor-based anti-cancer therapies: perspective on bortezomib and second generation proteasome inhibitors versus future generation inhibitors of ubiquitin\u2013proteasome system","volume":"14","author":"Dou","year":"2014","journal-title":"Curr Cancer Drug Targets"},{"issue":"6","key":"10.1016\/j.htct.2018.07.003_bib0400","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1111\/jcmm.12279","article-title":"Proteasome inhibitors \u2013 molecular basis and current perspectives in multiple myeloma","volume":"18","author":"Kubiczkova","year":"2014","journal-title":"J Cell Mol Med"},{"issue":"14","key":"10.1016\/j.htct.2018.07.003_bib0405","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"issue":"2","key":"10.1016\/j.htct.2018.07.003_bib0410","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.htct.2018.07.003_bib0415","unstructured":"FDA. 2015."},{"issue":"10","key":"10.1016\/j.htct.2018.07.003_bib0420","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1016\/S1470-2045(17)30578-8","article-title":"Carfilzomib or bortezomib in relapsed or refractory multiple myeloma (ENDEAVOR): an interim overall survival analysis of an open-label, randomised, phase 3 trial","volume":"18","author":"Dimopoulos","year":"2017","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0425","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0430","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/leu.2016.176","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","volume":"31","author":"Hajek","year":"2017","journal-title":"Leukemia"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0435","doi-asserted-by":"crossref","first-page":"e26","DOI":"10.1016\/j.clml.2017.03.045","article-title":"Phase 3 study (CLARION) of carfilzomib, melphalan, prednisone (KMP) v bortezomib, melphalan, prednisone (VMP) in newly diagnosed multiple myeloma (NDMM)","volume":"17","author":"Facon","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"26","key":"10.1016\/j.htct.2018.07.003_bib0440","doi-asserted-by":"crossref","first-page":"3360","DOI":"10.1182\/blood-2015-11-683854","article-title":"CHAMPION-1: a phase 1\/2 study of once-weekly carfilzomib and dexamethasone for relapsed or refractory multiple myeloma","volume":"127","author":"Berenson","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.htct.2018.07.003_bib0445","series-title":"59th ASH annual meeting","article-title":"Prospective study of cardiac events during proteasome inhibitor therapy for relapsed multiple myeloma","author":"Cornell","year":"2017"},{"issue":"2","key":"10.1016\/j.htct.2018.07.003_bib0450","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","article-title":"Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma","volume":"21","author":"Grandin","year":"2015","journal-title":"J Card Fail"},{"issue":"6","key":"10.1016\/j.htct.2018.07.003_bib0455","doi-asserted-by":"crossref","first-page":"2658","DOI":"10.2353\/ajpath.2010.090690","article-title":"Cardiotoxicity of the anticancer therapeutic agent bortezomib","volume":"176","author":"Nowis","year":"2010","journal-title":"Am J Pathol"},{"key":"10.1016\/j.htct.2018.07.003_bib0460","doi-asserted-by":"crossref","first-page":"e384","DOI":"10.1038\/bcj.2015.112","article-title":"Carfilzomib and the cardiorenal system in myeloma: an endothelial effect?","volume":"6","author":"Rosenthal","year":"2016","journal-title":"Blood Cancer J"},{"issue":"7","key":"10.1016\/j.htct.2018.07.003_bib0465","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1182\/bloodadvances.2016003269","article-title":"Cardiac and renal complications of carfilzomib in patients with multiple myeloma","volume":"1","author":"Dimopoulos","year":"2017","journal-title":"Blood Adv"},{"issue":"5","key":"10.1016\/j.htct.2018.07.003_bib0470","doi-asserted-by":"crossref","first-page":"1970","DOI":"10.1158\/0008-5472.CAN-09-2766","article-title":"Evaluation of the proteasome inhibitor MLN9708 in preclinical models of human cancer","volume":"70","author":"Kupperman","year":"2010","journal-title":"Cancer Res"},{"issue":"17","key":"10.1016\/j.htct.2018.07.003_bib0475","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0480","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1186\/s13045-017-0501-4","article-title":"Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma: China Continuation study","volume":"10","author":"Hou","year":"2017","journal-title":"J Hematol Oncol"},{"key":"10.1016\/j.htct.2018.07.003_bib0485","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.3324\/haematol.2017.170118","article-title":"Impact of prior therapy on the efficacy and safety of oral ixazomib-lenalidomide-dexamethasone vs placebo-lenalidomide-dexamethasone in patients with relapsed\/refractory multiple myeloma in TOURMALINE-MM1","volume":"102","author":"Mateos","year":"2017","journal-title":"Haematologica"},{"key":"10.1016\/j.htct.2018.07.003_bib0490","doi-asserted-by":"crossref","first-page":"107","DOI":"10.2147\/JBM.S102328","article-title":"New developments in the management of relapsed\/refractory multiple myeloma \u2013 the role of ixazomib","volume":"8","author":"Richardson","year":"2017","journal-title":"J Blood Med"},{"issue":"21","key":"10.1016\/j.htct.2018.07.003_bib0495","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1182\/blood.V118.21.302.302","article-title":"Phase 1 clinical evaluation of twice-weekly marizomib (NPI-0052), a novel proteasome inhibitor, in patients with relapsed\/refractory multiple myeloma (MM)","volume":"118","author":"Richardson","year":"2011","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2018.07.003_bib0500","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1111\/bjh.13780","article-title":"Synergistic anti-myeloma activity of the proteasome inhibitor marizomib and the IMiD immunomodulatory drug pomalidomide","volume":"171","author":"Das","year":"2015","journal-title":"Br J Haematol"},{"issue":"2","key":"10.1016\/j.htct.2018.07.003_bib0505","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","article-title":"Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions","volume":"179","author":"Moreau","year":"2017","journal-title":"Br J Haematol"},{"issue":"21","key":"10.1016\/j.htct.2018.07.003_bib0510","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1182\/blood.V124.21.3453.3453","article-title":"Oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: initial results from the dose escalation portion of a phase 1b\/2, multicenter open-label study","volume":"124","author":"Hari","year":"2014","journal-title":"Blood"},{"issue":"21","key":"10.1016\/j.htct.2018.07.003_bib0515","first-page":"84","article-title":"Clinical profile of single-agent modified-release oprozomib tablets in patients (Pts) with hematologic malignancies: updated results from a multicenter, open-label dose escalation phase 1b\/2 study","volume":"122","author":"Kaufman","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.htct.2018.07.003_bib0520","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1038\/leu.2015.356","article-title":"Management of relapsed multiple myeloma: recommendations of the International Myeloma Working Group","volume":"30","author":"Laubach","year":"2016","journal-title":"Leukemia"},{"issue":"13","key":"10.1016\/j.htct.2018.07.003_bib0525","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1182\/blood-2017-05-743203","article-title":"How I treat myeloma with new agents","volume":"130","author":"Moreau","year":"2017","journal-title":"Blood"},{"issue":"9758","key":"10.1016\/j.htct.2018.07.003_bib0530","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1016\/S0140-6736(10)61424-9","volume":"376","author":"Cavo","year":"2010","journal-title":"Lancet"},{"issue":"10068","key":"10.1016\/j.htct.2018.07.003_bib0535","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/S0140-6736(16)31594-X","article-title":"Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): a randomised, open-label, phase 3 trial","volume":"389","author":"Durie","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.htct.2018.07.003_bib0540","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.htct.2018.07.003_bib0545","doi-asserted-by":"crossref","first-page":"e504","DOI":"10.14694\/EdBook_AM.2015.35.e504","article-title":"Multiple myeloma: from front-line to relapsed therapies","author":"Moreau","year":"2015","journal-title":"Am Soc Clin Oncol Educ Book"},{"issue":"8","key":"10.1016\/j.htct.2018.07.003_bib0550","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1182\/blood-2012-02-408922","article-title":"Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA\/GEM study","volume":"120","author":"Rosinol","year":"2012","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.htct.2018.07.003_bib0555","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1158\/1078-0432.CCR-11-0853","article-title":"Molecular pathways: targeting proteasomal protein degradation in cancer","volume":"18","author":"Molineaux","year":"2012","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.htct.2018.07.003_bib0560","series-title":"15th international myeloma workshop","first-page":"e13","article-title":"Second-generation proteasome inhibition: what a difference a generation makes","author":"Boccadoro","year":"2015"}],"container-title":["Hematology, Transfusion and Cell Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113791830124X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S253113791830124X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,7,11]],"date-time":"2024-07-11T10:52:03Z","timestamp":1720695123000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S253113791830124X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,1]]},"references-count":56,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,1]]}},"alternative-id":["S253113791830124X"],"URL":"https:\/\/doi.org\/10.1016\/j.htct.2018.07.003","relation":{},"ISSN":["2531-1379"],"issn-type":[{"value":"2531-1379","type":"print"}],"subject":[],"published":{"date-parts":[[2019,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"New proteasome inhibitors in the treatment of multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Hematology, Transfusion and Cell Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.htct.2018.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Associa\u00e7\u00e3o Brasileira de Hematologia, Hemoterapia e Terapia Celular. Published by Elsevier Editora Ltda.","name":"copyright","label":"Copyright"}]}}